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1. Introduction 
 
The most common orbital disease with exophthalmos is 
Graves’ orbitopathy (GO), which is the extrathyroidal complication 
of Graves’ disease (GD). Graves’ orbitopathy usually appears 
simultaneously with or soon after the development of thyrotoxicosis; 
however, rarely it may precede hyperthyroidism.The clinical features 
of Graves’ orbitopathy are upper eyelid retraction, edema, and 
erythema of the periorbital tissues and conjunctivae, proptosis, dry 
ocular sensation, photophobia, double vision, and pressure sensation 
behind the eyes.  
The pathogenesis of GO is only partially understood; GO is 
probably initiatedby autoreactive T lymphocytes reacting with one or 
more antigensshared by the thyroid and orbit. The most probable 
shared thyroid-orbital autoantigens are the thyrotropin receptor and 
the IGF-I receptor. After reaching the orbit andrecognizing the 
shared antigen(s), T lymphocytestrigger a cascade of events, 
including secretion of cytokines. These cytokines stimulate the 
proliferation of orbital fibroblasts, expansion of adipose tissue, and 
production of hydrophilic glycosaminoglycans. B cells are involved 
as antigen-presenting and autoantibody-producingcells.  
Besides detailed ophthalmological examination (best-
corrected visual acuity, color vision, pupillary examination, ocular 
motility, Hertel’s exophthalmometry, intraocular pressure, adnexal 
examination, slit-lamp examination, dilated fundus examination) 
laboratory parameters that are necessary to confirm the diagnosis 
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include: measurement of serum thyroid stimulating hormone, free 
thyroxin, and TSH receptor antibody levels. In euthyreoid Graves’ 
orbitopathy, TSH receptor antibody level is elevated without any 
thyroid function abnormality.  
The diagnosis of Graves’ orbitopathy in most patients is 
obvious; however, exophthalmos can also be present in patients with 
lymphoproliferative disorders of the orbits, idiopathic orbital 
inflammatory syndrome, orbital myositis, severe obesity, Cushing’s 
syndrome, histiocytosis, granulomatosis with polyangitis, and IgG4-
related orbitopathy (IgG4-rd). Orbital magnetic resonance imaging, 
orbital computed tomographyand/or single photon emission 
computed tomography and histology (if necessary) can help to 
distinguish between the underlying causes. 
Treatment of severe, active GO remains a therapeutic 
challenge. 
Rituximab, a chimeric anti-CD20 antibody and is approved 
for treatment of B-cell lymphoma in adults. It is used in autoimmune 
diseases including immune thrombocytopenic purpura, systemic 
lupus erythematosus, myasthenia gravis and rheumatoid arthritis. 
CD20 (human B-lymphocyte-restricted differentiation antigen, 
Bp35) is a hydrophobic transmembrane protein with a molecular 
weight of approximately 35 kD. The antigen is expressed on the 
surface of pre-B and mature B lymphocytes, but not on stem cells, 
pro-B lymphocytes, and plasma cells. CD20 regulates early steps in 
the activation process for cell cycle initiation and differentiation. 
Three different mechanisms have been proposed for the elimination 
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of B cells by anti-CD20: complement-dependent cytotoxicity (CDC), 
antibody-dependent cellular cytotoxicity (ADCC) and stimulation of 
the apoptotic pathway. Anti-CD20 has become a clinically relevant 
treatment option in selected cases of GO. Some authors have shown, 
in preliminary work, that anti-CD20 has affected the clinical course 
of GO positively by binding to the CD20 receptor on B lymphocytes. 
The mechanism by which anti-CD20 influences the clinical course of 
GO is largely unknown. In addition to influencing the cytokine 
production in the orbit by inducing depletion of antigen presenting 
B-cells, the action of anti-CD20 therapy may also involve 
autoreactive T cells. Phagocytes and other inflammatory cells not 
only remove anti-CD20-opsonized B cells, but at the same time 
remove autoreactive T cells interacting with them in peripheral 
lymphoid organs. That could be the explanation for the unexpected 
efficacy of anti-CD20 in the treatment of predominantly T helper cell 
mediated autoimmune diseases, including rheumatoid arthritis. 
 
 
2. Aims 
 
 Create an algorithm to distinguish between GO and IgG4 
orbitopathy 
 Study the short-term effect of anti-CD20 treatment in severe, 
treatment-resistant GO 
 Study the long-term effect of anti-CD20 treatment in severe, 
treatment-resistant GO 
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 Study the effect of anti-CD20 treatment on the autoimmune 
process and hyperthyroidism in GD patients  
 Study the short and long-term side-effects of anti-DC20 
treatment 
 
 
3. Patients and methods 
 
3.1. Patients 
Five patients, four women and one man, aged 31-64 year 
(47.8±12.2) were entered in the study. All had severe, treatment-
resistant, active GO. The study protocol required either no 
improvement or worsening of clinical activity of the disease after a 
recent course of intravenous methylprednisolone totalling at least 3 
grams within the 6 weeks preceding initiation of rituximab therapy. 
The combination of the steroids with 20 Gy retrobulbar irradiation 
by a linear accelerator was allowed for entry. Inclusion criterion was 
the activity of GO confirmed by three independent techniques: 
clinical activity score (CAS) [23], 99mTc-labeled diethylene-triamine-
pentaacetic-acid (99mTc DTPA) single photon emission computed 
tomography (SPECT), and orbital magnetic resonance imaging (MR) 
[24]. Disease activity criteria for inclusion were as follows: CAS  4, 
DTPA uptake  20 % above normal on orbital SPECT, and T2 
relaxation time  20% above normal in at least one muscle on MR. 
Patients were ineligible if they had hypothyroidism, severe 
hyperthyroidism, previous orbital decompression surgery, fever, 
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previous treatment with any other monoclonal antibody, allergy that 
needed continuous medication, pregnancy, breast-feeding, or 
operation in general anaesthesia in the last four weeks. 
Four patients were smokers and one patient was ex-smoker. At the 
time of anti-CD20 therapy, patients were euthyroid or mildly 
hyperthyroid, one on propylthiouracyl, two on methimazole 
combined with L-thyroxine, and two patients on L-thyroxine after 
previous thyroidectomy. Thyroidectomies were performed one and 
two years before anti-CD20 treatment in patients 3 and 4, 
respectively. TSH receptor antibody (TRAb) level was elevated in all 
patients. All patients had received methylprednisolone, 3 grams or 
more, within the 6 weeks preceding initiation of anti-CD20 therapy, 
and two of them also underwent retrobulbar irradiation 3 months 
earlier than anti-CD20 treatment was given. 
 
3.2. Study design 
Before anti-CD20 treatment, thyroid function tests, TSH 
receptor antibodies and B lymphocyte counts were measured in all 
patients. Initial disease activity parameters were assessed within the 
last 2 weeks before anti-CD20 treatment. All laboratory parameters 
were repeated at 1, 3, 6, 12 months afterthe first anti-CD20 infusion. 
Thereafter thyroid function tests and TSH receptor antibody levels 
were measured if required by health-conditions changes, but at least 
in once on a yearly basis. The mean follow-up period was 67 months 
(range: 58 to 81 months). Visits included detailed ophthalmological 
examination. CAS was calculated inorder to monitor the clinical 
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improvement of the patients. Orbital DTPA SPECT and MR T2 
relaxation time measurements were performed before the first RTX 
infusion and 3 and 12 months thereafter. Changes of T2 relaxation 
times of the muscle with the longest T2 relaxation time at study entry 
in each orbit were separately analyzed.  
Anti-CD20 was a chimeric human–mousemonoclonal 
antibody by Hoffman La Roche, Basel, Switzerland (rituximab, 
MabThera).The therapeutic protocol was the one established for 
treatmentof patients with B cell lymphoma: anti-CD200 was given as 
weekly infusions of 375 mg/m2 body surface area for 4 weeks. One 
hour prior to anti-CD20 infusion, paracetamol (500 mg), 
metimazolnatrium (500 mg) and calcium gluconat (5 ml) were 
administered orally and methylprednisolone (80 mg) intravenouslyto 
prevent possible allergic reactions. During the infusion, heart rate 
and blood pressure were monitored. Patients left the clinic 2 hours 
after completion of the treatment session. All 5 patients received a 
full anti-CD20 course and were included in the analyses. 
The Hungarian National Review Board and the Institutional Ethics 
Committee approved the study protocol and ensured that written 
informed consent was obtained from all patients. 
 
3.3. Biochemical and immunological measurements, 
cytofluorimetric analysis 
Serum TSH, fT4, fT3 concentrations were measured using 
the electrochemiluminescence immunoassay technique (ECLIA) on 
the Modular Analytics E170 analyser (Roche Diagnostics, 
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Mannheim, Germany). TSH receptor antibodies,detected as TSH 
binding inhibitory immunoglobulins, were measuredusing I125 
labelled competitive radio-receptor assay (BRAHMS TRAK human 
RIA, Henningsdorf, Germany) on the Ria-mat 280 analyser (Stratec, 
Birkenfeld, Germany). Reference ranges were as follows: TSH: 0.3-
4.2 mIU/L, fT4: 12-22 pmol/L, fT3: 2.4-6.3 pmol/L, TRAK: <1 
IU/L. 
CD20+ cells were counted using anti-CD20 FITC-conjugated 
monoclonal mouse anti-human reagent (BD Biosciences, 
Erembodegem-Aalst, Belgium) on the BD FACSTM brand flow 
cytometer. BD CellQuest software was used for data acquisition and 
analysis (BD Biosciences, Becton, Dickinson and Company, San 
Jose, California, USA). 
 
3.4. Imaging techniques 
3.4.1. MR 
MR of the orbits has been performed in a conventional 1.5 
T MR unit (GE Excite, General Electric, Milwaukee, USA). 
Following STIR, T1 and T2 weighted coronal images, sagittal and 
axial non-contrast T1 weighted fast spin echo images were also 
taken. All scans were acquired consecutively with 3 mm slice 
thickness. Axial and sagittal planes were chosen to be parallel with 
the course of the optic nerve. Additionally, multisection-multiecho 
T2 weighted sequences were prepared in the coronal plane 
(TR=2020 ms; TE= between 12-180 ms using 14 echos) with 4 mm 
slice thickness. To avoid inaccuracies resulting from rectus and 
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orbicularis muscle contraction, the subjects were asked to keep their 
globe in a neutral position and to close their eyes gently. 
T2 relaxation maps were calculated on pixel-by-pixel by using a 
linear least squares curve-fitting monoexponential algorithm. T2 
relaxation time of ocular muscles was measured on T2 relaxation 
time maps using region-of-interest (ROI) assignment.  
 
3.4.2. SPECT 
Shortly, 7MBq/kg 99mTc-DTPA (PromtCarry, Szeged, 
Hungary) was administered intravenously. After 20 minutes, a 
Nucline X-Ring four headed SPECT device (Mediso, Budapest, 
Hungary) was used for imaging. One hundred twenty-eight frames 
were acquired in step-and-shoot mode. After iterative reconstruction 
and absorption correction, coronal and sagittal slice sets were 
generated perpendicularly to the transversal plane, covering the 
entire orbital area. To quantify DTPA accumulation in the orbits, 
regions of interest were drawn on the transversal slices, outlining 
areas corresponding to the right and left orbits. The sum of the six 
transaxial slices containing the entire orbital region was used in 
uptake calculations. The DTPA uptake was the fraction of the 
injected dose taken up by the selected regions of interest. DTPA 
uptake activities obtained by SPECT before and after treatment were 
compared. 
 
3.5. Statistical analysis 
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Statistical analyses were performed using the SAS for 
Windows 8.2 (Cary Inc., SAS Institute Inc. USA) statistical package. 
Descriptive statistics were given as the meanstandard deviation 
(SD). The changes of serum TSH receptor antibodies, CAS values 
and DTPA uptakes were analyzed by ANOVA (post-hoc Scheffe and 
Newman-Keuls tests). To compare the T2 relaxation time values 
before and after treatment, we used a paired sample t-test. The 
p0.05 probability level was accepted as significant. 
 
 
4. Results 
 
4.1. Effects of anti-CD20 treatment: B-cell depletion 
The proportion of CD20+ lymphocytes was 3.62±1.45 % at 
the beginning of the study. All patients attained peripheral B-cell 
depletion with anti-CD20 treatment; CD20+ cell number dropped to 
0 % after anti-CD20 infusions. CD20+ cell counts started to increase 
after 6 months (0.19±0.2 %) and failed to reach the pre-treatment 
values at 12 months (1.74±0.87 %) in any of the patients. 
All patients tolerated anti-CD20 treatment well. A minor side effect 
(localized skin erythema) was detected in one patient during the first 
infusion. The infusion was continued and the erythema disappeared 
within 1 hour. 
 
4.2. Effect of anti-CD20 treatment on the activity and course of 
GO  
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In all patients treated with anti-CD20antibody, a definite 
clinical improvement of GO has been observed. The mean CAS 
before therapy was 6.5±1.72 and decreased to 3.4±1.58 by 1 month 
and remained unchanged afterwards (3.2±1.75 at 12 months, 
p<0.05). No further CAS change, in either direction, was detected 
during the yearly follow up visits. 
On the SPECT images, the mean DTPA uptake before 
therapy was 16.52±4.51 MBq/cm3, which decreased to 13.30±2.06 at 
3 month, and further to 11.97±2.36 MBq/cm3 at one year (ANOVA, 
p<0.002,).  
The mean of T2 relaxation times on MR images (n=40 
muscles) before therapy was 96.91±17.61 ms and decreased to 
84.29±9.41 ms by the end of one year follow-up period (t-test, 
p<0.001). We studied separately the most severely involved external 
eye muscles in each orbit (10 muscles in 5 patients). In these 
muscles, the mean of T2 relaxation time was 112.80±14.38 ms 
before anti-CD20 treatment and dropped to 83.99±12.66 ms by the 
12th month (p<0.01,).  
 
4.3. Effects of anti-CD20 treatment on thyroid autoantibodies  
After anti-CD20 treatment, a decline of TRAb level was 
noted in all patients: the mean serum TRAb level was 7.44±3.36 U/L 
before therapy, 5.6±4.5 U/L at the 1 month control visit and 
1.68±1.52 U/L at one year. The difference between the 0 and 12 
months values is statistically significant (Scheffe test; p<0,004).  No 
correlations between changes of TRAb and activity parameters 
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(CAS, DTPA uptake, T2 relaxation time) were found. TRAb values 
remained low in 4 of 5 patients throughout the 5 years follow up.  
Before anti-CD20 treatment, patients were either euthyroid 
or mildly hyperthyroid, one on propylthiouracyl, two on 
methimazole combined with L-thyroxine, and two patients on L-
thyroxine after previous thyroidectomy. Methimazole and 
propylthiouracyl treatment could be terminated during the first six 
months after anti-CD20 treatment (2.6  2,1 months). The serum 
TSH level was 0.24±0.16 mU/L before anti-CD20 therapy and 
0.81±0.91 mU/L 12 months later. Serum fT3 was 5.88±1.24 pmol/L 
before therapy and 5.04±0.99 pmol/L at 12 months; serum fT4 was 
21.52±6.54 before therapy and 21.10±6.16 at 12 months. While we 
did not detect relapse of hyperthyroidism in any of the patients at the 
one year follow up visit, in one patient TRAb positivity and relapse 
of hyperthyroidism occurred at 3 years. 
 
 
5. Discussion 
 
 
The diagnosis of Graves’orbitopathy in most patients is obvious; 
however, exophthalmos can also be present in patients with 
lymphoproliferative disorders of the orbits, idiopathic orbital 
inflammatory syndrome, severe obesity, Cushing’s syndrome, 
histiocytosis, granulomatosis with polyangitis, and IgG4-related 
orbitopathy. Orbital magnetic resonance imaging, orbital computed 
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tomographyand/or single photon emission computed tomography 
with histological examination (if necessary) can help to distinguish 
between the underlying causes. 
IgG4-rd is a recently described and increasingly recognized 
entity which may present with involvement of the eyes, termed 
IgG4-related orbitopathy. IgG4-rd usually affects more than one 
organ, typically the orbits, salivary glands, lungs, pancreas, biliary 
ducts and retroperitoneal tissue. Orbital involvement most frequently 
includes the lacrimal glands and extraocular muscles, however, 
infraorbital and supraorbital nerve enlargement may also be detected. 
In a series of 1014 orbital lymphoproliferative disease cases, the 
incidence of IgG4-related orbitopathy was found to be 21.6 %. 
Features of IgG4-rd include tumor-like swelling of involved organs, 
lymphoplasmacytic tissue infiltration enriched in IgG4-positive 
plasma cells, storiform fibrosis and obliterative phlebitis. The 
number of IgG4-positive plasma cells per high-power field (HPF) 
that is regarded as consistent with or suggestive of IgG4-rd varies 
some what from tissue to tissue. Generally, the minimum for making 
the diagnosis for most tissues is from 30 to 50 IgG4-positive 
cells/HPF. However, in the lacrimal gland, 10 IgG4-positive 
plasmacells/HPF may be sufficient for the diagnosis. Storiform 
fibrosis and obliterative phlebitis are more typical of the systemic 
pathology; however, they are not always present in the orbital 
disease. A specific autoantigenic target has not been identified; 
furthermore, it is not clear whether the IgG4 antibodies are 
pathogenic. In 2009, diagnostic criteria for IgG4-rd were proposed, 
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and comprehensive diagnostic criteria are currently in use. In 
patients with typical clinical features and organ involvements both 
measurement of serum IgG4 levels and tissue biopsy are 
recommended. Elevated serum concentrations of IgG4 are found in 
60-70 percent of patients with IgG4-rd, but this finding is not 
specific, as it can also be associated with Churg-Strauss syndrome, 
sarcoidosis and allergic diseases.  
All patients with symptomatic active IgG4-rd require treatment. 
Glucocorticoids are the first-line agents for remission induction. 
Following a successful course of induction therapy, certain patients 
benefit from maintenance therapy. Repeated glucocorticoid courses 
are indicated in patients who relapse following successful remission 
induction. Most patients respond to glucocorticoids within several 
weeks, typically with symptomatic improvement, reduction in the 
size of masses or enlarged organs, improvement in organ function, 
and a decrease in serum levels of IgG4. In those who are resistant to 
glucocorticoids, or have side effects or contraindications to 
glucocorticoid therapy, anti-CD20 is another therapeutic option. 
Neither the natural course nor the prognosis of IgG4-rd is well-
understood. Spontaneous improvements can be seen, but the disease 
often relapses if left untreated. Symptoms respond dramatically to 
glucocorticoids, but relapses are common following discontinuation 
of therapy. Significant organ dysfunction may arise from 
uncontrolled and progressive inflammatory and fibrotic changes in 
affected tissues. Currently, it is uncertain if there is an increased risk 
of malignancy in patients with IgG4-related disease, however, 
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lymphomas occur more frequently in patients with IgG4-related 
disease. 
The prevalence of the disease could be more frequent than it is 
diagnosed. There is enhanced attention towards IgG4-related 
orbitopathy in Japan, as well as few published cases in Europe.  
The most typical manifestations of IgG4-related orbitopathy are 
the usually easily detectable dacryoadenitis, swollen eyelid and 
involvement of extraocular muscles. The external eye muscle 
involvement pattern on MRI is distinct from Graves’ orbitopathy, 
where the inferior and medial rectuses are the most frequently 
involved muscles. In IgG4-related orbitopathy these muscles are 
often spared, as seen in our case. Less commonly, compressive optic 
neuropathy secondary to mass effect from inflammatory lesions may 
result in visual loss, afferent pupillary defect, or visual field 
defects. Mass effect can particularly occur in patients with 
infraorbital nerve enlargement, which is defined as the infraorbital 
nerve being greater in diameter than the optic nerve. Infraorbital 
nerve enlargement is significantly correlated with elevated serum 
IgG4 levels. Sensory loss is extremely rare. Other less common 
manifestations are frontal nerve and perioptic nerve lesions. 
Involvement of the nasolacrimal duct system can cause epiphora. In 
rare cases of IgG4-related orbitopathy causing scleritis, patients may 
present with conjunctival and scleral injection with blurred vision. 
Data on the association of IgG4-rd and Hashimoto’s or Riedel’s 
thyreoiditis exist, but similar association with Graves’ disease has 
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not been described. Notably, one group found elevated IgG4 levels 
in 6.4 % of 109 patients with Graves’ disease. This subgroup of 
patients was significantly older, their symptoms were manageable 
with small doses of antithyroidal drugs and they were prone to be 
hypothyroid after treatment. It has recently been shown that IgG4 
levels may be elevated in newly diagnosed Graves’ disease patients 
compared with euthyroid subjects and in the presence of Graves’ 
orbitopathy compared with the absence of Graves’ orbitopathy. 
However, the IgG4 rise in IgG4-rd is more marked. Corticosteroid 
treatment is the standard therapeutic option for both Graves’ 
orbitopathy and IgG4-related orbitopathy, but unlike in Graves’ 
orbitopathy, marked response to low corticosteroid doses is typical in 
IgG4-related orbitopathy. 
IgG4-related orbitopathy may easily be mistaken for Graves’ 
orbitopathy. All patients with suspected euthyroid Graves’ 
orbitopathy in whom TSH receptor autoantibodies are not present 
have to be evaluated for IgG4-related orbitopathy. Once IgG4-
related orbitopathy is proven, other manifestations of IgG4-rd have 
to be searched for; lifelong follow up is required. Immunoglobulin 
G4-related disease is an increasingly recognized syndrome of 
unknown etiology. IgG4-rd could affect many organs and tumor-like 
swelling of the involved organs is common. Several of the 
manifestations typically occur in the same patient. The diagnosis of 
IgG4-rdis based upon biopsy findings (IgG4 positive 
lymphoplasmacytic infiltration and tissue fibrosis). Serum IgG4 level 
should be measured, and isolated elevated levels support the 
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diagnosis, although it is not fully diagnostic without histological 
examination. Due to various manifestations of this new entity, a 
multidisciplinary approach is warranted.  
Corticosteroid resistant, progressive GO remains a therapeutic 
challenge. In the present series, we found that anti-CD20 monoclonal 
antibody had beneficial effect on disease activity in all five patients 
with treatment-resistant, severe, active GO. The immediate decrease 
in disease activity parameters CAS and DTPA, at 1 and 3 months, 
respectively, in patients who failed to respond to conventional 
therapy, was striking. The positive effect remained permanent for 5 
years. To our knowledge, this is the longest published follow up of 
anti-CD20 treatment in GO.  
The initially elevated TRAb levels were reduced at 12 
months after anti-CD20.Thyroid function of those patients who had 
required antithyroid medication, returned to the normal range within 
6 months. Relapse of hyperthyroidism was detected in one of the 3 
medically treated patients at the 3 year follow up visit.  
Effectiveanti-CD20 treatment in severe active GO has also been 
reported by other groups. However, the effect on TRAb levels and 
the outcome of Graves’ hyperthyroidism has been controversial. We 
found that anti-CD20 administered in a high dose compared to doses 
used in the majority of previous studies, devided over a 4 week 
period, significantly reduced TRAb levels, and was able to influence 
the course of Graves’ hyperthyroidism with a comparative 
effectiveness to conventional medical therapies.  
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However, as the cost of anti-CD20 is substantially higher 
than that of antithyroid drugs, we think that anti-CD20 treatment is 
not suitable option for unselected cases of Graves’ hyperthyreoidism. 
It is tempting to speculate that the more favorable outcome of anti-
CD20 in this respect may be the consequence of the therapeutic 
protocol we used: in our series, the full lymphoma dose has been 
administrated, i.e. 375 mg/m2 anti-CD20 infusions were given 
weekly for 4 consecutive weeks. Of the studies detailed above, one 
group used the same regimen in their two worksand in fact, their 
findings are nearly identical. The schedule used by another groups, 
1.0 g anti-CD20given twice 2 weeks apart, failed to result in any 
reduction in the TRAb levels. Neither in their, nor in our study did 
CAS changes correlate with TRAb levels. This could mean that the 
favorable effect of anti-CD20 in GO is not a direct consequence of 
the declining TRAb production, this speculation is supported by the 
fact that beneficial effect of anti-CD20 treatment on GO was 
observed in very low dose and with intraocular use. 
The limitation of our study is that some of the favorable 
orbital changes seen after anti-CD20 treatment may be related to the 
recent administration of intravenous corticosteroids, or to the use of 
corticosteroid as premedication before anti-CD20 infusions. 
Additionally the slowly developing effect of irradiation in 2 of the 
patients as well as the spontaneous fluctuations during the natural 
course of the disease may have contributed to the clinical effect. 
Similarly, previous thyroidectomy in 2 patients may have had a 
positive effect on both GO course and TRAb level. However, the 
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fact that improvements occurred within 30 days after anti-CD20 
administration in patients who had shown no response to high dose 
corticosteroids, and the effect remained stable for 5 years, strongly 
supports the notion that anti-CD20 exerts its effect at one or several 
factors of the pathogenesis of GO. Another limitation is the low 
number of patients studied. With improving endocrine care and early 
detection of GO, severe therapy resistant cases are infrequent; it took 
19 months to recruit five patients with steroid resistant GO for the 
study. In spite of the small number of patients, the improvement of 
all three disease activity parameters followed were statistically 
significant.  
We detected only one minor side effect (localized skin 
erythema) of anti-CD20 in one patient during the first infusion. 
Benign infusion related adverse events are common. El Fassi 
reported articular adverse events and gastrointestinal symptomps in 
GD patients who received anti-CD20. Others investigated mortality 
associated with rituximab use in autoimmune diseases and they 
found the mortality rate of 2.4 % in patients with autoimmune 
disease treated with anti-CD20. Among them, 75 % died from 
infections. In the case of GO patients, anti-CD20 should be restricted 
for the most severe cases. 
We believe that all patients with conventional therapy 
resistant Graves’ orbitopathy are candidates for anti-CD20 treatment 
administered according to the lymphoma protocol. This may prevent 
disease progression and help to avoid orbital decompression surgery. 
In addition to reporting that anti-CD20 administered according to the 
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lymphoma protocol is effective in severe GO, we provided proof of 
its efficacy by three independent methods, CAS, MR and SPECT. If 
severe active GO is present, anti-CD20 may be a useful therapeutic 
choice if conventional therapies, including steroids and irradiation 
fail.  
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6. Summary of the new results 
 
 We worked out an algorithm for the differential diagnosis of the 
endocrine orbitopathy and IgG4 orbitopathy 
 We administrated anti-CD20 therapy for treatment of endocrine 
orbitopathy first time in Hungary. The treatment improved the 
clinical signs and the activity of the disease rapidly and this effect 
was stable during the 5 years follow-up. 
 Decrease in TSH receptor antibody level was significant at 12 
months follow-up; however improvement in orbita process was mark 
able at 1 month after the treatment. Our resultssuggest that effect of 
anti-CD20 therapy is not due the decrease of TSH receptor antibody 
level. Anti-Cd20 treatment influenced favorably the autoimmune 
process against thyroid and the hyperthyroidism. 
 We did not detect severe side effect beside the anti-CD20 treatment. 
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